4.5 Article

Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016

Journal

JOURNAL OF RHEUMATOLOGY
Volume 44, Issue 10, Pages 1522-1528

Publisher

J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.160904

Keywords

PSORIATIC ARTHRITIS; CORE SET; OUTCOME MEASURES

Categories

Funding

  1. Scientist Development Award from the Rheumatology Research Foundation
  2. Johns Hopkins Arthritis Center Discovery Fund
  3. US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [K23 AR063764]
  4. (RDRCC Human Subjects Research Core) from NIAMS [P30-AR053503]
  5. Camille J. Morgan Arthritis Research and Education Fund
  6. Celgene
  7. Janssen
  8. AbbVie
  9. Pfizer
  10. National Institute for Health Research [RP-PG-1212-20007]
  11. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
  12. OMERACT
  13. National Institute for Health Research [CL-2011-02-001, RP-PG-1212-20007] Funding Source: researchfish

Ask authors/readers for more resources

Objective. To include the patient perspective in accordance with the Outcome Measures in Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials (RCT) and longitudinal observational studies (LOS). Methods. At OMERACT 2016, research conducted to update the PsA Core Domain Set was presented and discussed in breakout groups. The updated PsA Core Domain Set was voted on and endorsed by OMERACT participants. Results. We conducted a systematic literature review of domains measured in PsA RCT and LOS, and identified 24 domains. We conducted 24 focus groups with 130 patients from 7 countries representing 5 continents to identify patient domains. We achieved consensus through 2 rounds of separate surveys with 50 patients and 75 physicians, and a nominal group technique meeting with 12 patients and 12 physicians. We conducted a workshop and breakout groups at OMERACT 2016 in which findings were presented and discussed. The updated PsA Core Domain Set endorsed with 90% agreement by OMERACT 2016 participants included musculoskeletal disease activity, skin disease activity, fatigue, pain, patient's global assessment, physical function, health-related quality of life, and systemic inflammation, which were recommended for all RCT and LOS. These were important, but not required in all RCT and LOS: economic cost, emotional well-being, participation, and structural damage. Independence, sleep, stiffness, and treatment burden were on the research agenda. Conclusion. The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps for the PsA working group include evaluation of PsA outcome measures and development of a PsA Core Outcome Measurement Set.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE

Philip J. Mease, Akihiko Asahina, Dafna D. Gladman, Yoshiya Tanaka, William Tillett, Barbara Ink, Deepak Assudani, Christine de la Loge, Jason Coarse, Jason Eells, Laure Gossec

Summary: This study evaluated the effects of long-term bimekizumab treatment on symptoms and impact of PsA on patients. The results showed sustained improvements in pain and fatigue, reducing the overall impact of PsA on patients. Physical function and quality of life also improved up to 3 years.

RHEUMATOLOGY (2023)

Article Rheumatology

The effect of group-based cognitive behavioural therapy for insomnia in patients with rheumatoid arthritis: a randomized controlled trial

Kristine M. Latocha, Katrine B. Loppenthin, Mikkel Ostergaard, Poul J. Jennum, Merete L. Hetland, Henrik Rogind, Tine Lundbak, Julie Midtgaard, Robin Christensen, Bente A. Esbensen

Summary: The objective of the study was to compare the effects of cognitive behavioural therapy for insomnia (CBT-I) to usual care on sleep efficiency. The study found that CBT-I did not significantly improve sleep efficiency measured by polysomnography (PSG). However, CBT-I showed significant improvement in patient-reported sleep and RA-related outcomes.

RHEUMATOLOGY (2023)

Article Orthopedics

Who are likely to benefit from the Good Life with osteoArthritis in Denmark (GLAD) exercise and education program? An effect modifier analysis of a randomised controlled trial

M. Henriksen, S. M. Nielsen, R. Christensen, L. E. Kristensen, H. Bliddal, C. Bartholdy, M. Boesen, K. Ellegaard, D. J. Hunter, R. Altman, E. Bandak

Summary: This study aimed to identify contextual factors that modify the treatment effect of the GLAD exercise and education programme compared to open-label placebo on knee pain in individuals with knee OA. The results suggest that patients who take analgesics or report constant knee pain seem to benefit more from the GLAD programme compared to OLP in terms of knee pain.

OSTEOARTHRITIS AND CARTILAGE (2023)

Review Rheumatology

Treating spondyloarthritis early: does it matter? Results from a systematic literature review

Dafne Capelusnik, Diego Benavent, Desiree van der Heijde, Robert Landewe, Denis Poddubnyy, Astrid van Tubergen, Louise Falzon, Victoria Navarro-Compan, Sofia Ramiro

Summary: This study conducted a systematic literature review to summarize the relationship between early treatment and treatment clinical response in patients with SpA. It found that early treatment was associated with better outcomes in patients with non-radiographic axSpA and symptom duration of less than 5 years, but no differences in response to treatment were found in radiographic axSpA or in patients with longer symptom duration.

RHEUMATOLOGY (2023)

Article Rheumatology

The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter?

Casper Webers, Uta Kiltz, Juergen Braun, Desiree van der Heijde, Annelies Boonen

Summary: Treating active SpA improves depressive symptoms, especially with TNF inhibitors (TNFis) which have a stronger effect mainly due to their impact on disease activity.

RHEUMATOLOGY (2023)

Editorial Material Rheumatology

Current treatment strategies and recommendations in psoriatic arthritis

Pei-En Kao, Yung-Heng Lee, Kevin Sheng-Kai Ma, Amy Ker, Ying-Ying Leung

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2023)

Article Immunology

Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING)

Margaret Ma, Amelia Santosa, Warren Fong, Li-Ching Chew, Andrea H. L. Low, Annie Law, Yih Jia Poh, Siaw Ing Yeo, Ying Ying Leung, Victoria W. W. Ng, Joshua Z. E. Koh, Sen Hee Tay, Anselm Mak, Gim Gee Teng, Chuanhui Xu, Johnston G. X. Tang, Kok Ooi Kong, Stanley Angkodjojo, Wei-Rui Goh, Tyng Yu Chuah, Nur Emillia Roslan, Thaschawee Arkachaisri, Kai Liang Teh, Melonie Sriranganathan, Teck Choon Tan, Kee Fong Phang, Qai Ven Yap, Yiong Huak Chan, Peter P. M. Cheung, Manjari Lahiri

Summary: A national retrospective cohort study found a moderately high rate of flares of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination, but also improvement in several patients. Severe flares and hospitalization were rare. Thus, vaccination remains safe and highly recommended.

JOURNAL OF AUTOIMMUNITY (2023)

Article Rheumatology

The Effects of Continuity of Rheumatology Care on Emergency Department Utilization and Hospitalizations for Individuals With Early Rheumatoid Arthritis: A Population-Based Study

Abel Davtyan, Jennifer J. Y. Lee, Lihi Eder, Gillian A. Hawker, Jin Luo, Claire E. H. Barber, J. Carter Thorne, Jessica Widdifield

Summary: A study found that continuity of rheumatology care influences rates of emergency department visits and hospitalizations in patients with rheumatoid arthritis (RA). Patients who received continuous rheumatology care during the first 5 years after diagnosis had lower rates of ED visits and hospitalizations compared to those who did not receive continuous care. This study provides evidence supporting the value of early and continuous rheumatology care for reducing hospitalizations and ED visits.

JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial

L. Uhrenholt, R. Christensen, L. Dreyer, E-M Hauge, A. Schlemmer, A. G. Loft, M. N. B. Rasch, H. C. Horn, K. H. Gade, R. D. Ostgard, P. C. Taylor, K. Duch, S. Kristensen

Summary: This study aimed to evaluate whether disease activity-guided tapering of biologics enables a significant dose reduction while maintaining equivalent disease activity. The results showed that disease activity-guided tapering of biologics allowed one-third of the patients to achieve a reduction of 50% or more, while disease activity remained equivalent between the tapering and control groups. Although flare rates were higher in the tapering group, they could be managed with rescue therapy.

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Prevalence of survey-based criteria for fibromyalgia and impact on hospital burden: a 7 year follow-up study from an outpatient clinic

P. R. Lage-Hansen, S. Chrysidis, K. Amris, S. Fredslund-Andersen, R. Christensen, T. Ellingsen

Summary: This study evaluated the prevalence of survey-based fibromyalgia (FM) criteria among newly referred patients in a rheumatic outpatient clinic, and compared the use of healthcare services between survey-based FM and non-FM cases. The study found that FM cases were more likely to be women and received more medications and public economic support. FM cases also had a higher number of hospital courses and had undergone more invasive procedures compared to non-FM cases. Consultations with various specialists were also more frequent for FM cases.

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Patient-defined flares and disease activity worsening in 222 patients with psoriatic arthritis from 14 countries

Marlene Sousa, Ennio Lubrano, Josef S. Smolen, Clemence Gorlier, Maarten de Wit, Laura C. Coates, Umut Kalyoncu, Adeline Ruyssen-Witrand, Ying-Ying Leung, Rossana Scrivo, Juan D. Canete, Penelope Palominos, Sandra Meisalu, Andra Balanescu, Uta Kiltz, Sibel Zehra Aydin, Inna Gaydukova, Emmanuelle Dernis, Bruno Fautrel, Ana-Maria Orbai, Laure Gossec

Summary: This study aimed to explore patient-defined flares in psoriatic arthritis (PsA) and compare them to an increase in disease activity in psoriatic arthritis (DAPSA). The validity of a patient-reported flare question was also analyzed. The results showed that patient-reported flares were associated with disease activity and symptoms, and there was moderate agreement between patient and physician definitions of worsening.

JOINT BONE SPINE (2023)

Review Rheumatology

The evolving demographics of participants in psoriatic arthritis phase III randomised controlled trials of b/tsDMARDs: A systematic review

Wendy Zhu, Sally Ayoub, Eric Morand, William Tillett, Anna Antony

Summary: This study conducted a systematic review of participants recruited for phase III RCTs of b/tsDMARDs in peripheral PsA and found that despite the increase in countries involved, the proportion of white participants did not significantly change and non-white participants continue to be underrepresented. Improving diversity in patient representation is crucial for advancing our understanding and treatment of psoriatic disease.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2023)

Article Rheumatology

Derivation of a Multivariable Psoriatic Arthritis Risk Estimation Tool (PRESTO): A Step Towards Prevention

Lihi Eder, Ker-Ai Lee, Vinod Chandran, Jessica Widdifield, Aaron M. Drucker, Christopher Ritchlin, Cheryl F. Rosen, Richard J. Cook, Dafna D. Gladman

Summary: The study aimed to develop a risk prediction model for psoriasis patients to predict their risk of developing psoriatic arthritis (PsA) and evaluate its performance. The results showed that using readily available clinical variables, the development of PsA within clinically meaningful time frames can be predicted with reasonable accuracy for psoriasis patients.

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort

E. Gremese, Francesco Ciccia, Carlo Selmi, Giovanna Cuomo, Rosario Foti, Marco Matucci-Cerinic, Fabrizio Conti, Enrico Fusaro, Giuliana Guggino, Florenzo Iannone, Andrea Delle Sedie, Roberto Perricone, Luca Idolazzi, Paolo Moscato, Elke Theander, Wim Noel, Paul Bergmans, Silvia Marelli, Laure Gossec, Josef S. Smolen

Summary: This study compared the real-world persistence, effectiveness, and tolerability of ustekinumab and TNFi in PsA patients. The results showed that ustekinumab had better persistence than TNFi, overall and in specific subgroups. After one year of treatment, both ustekinumab and TNFi showed similar effectiveness.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (2023)

Article Rheumatology

Clinical significance of a self-reported familial occurrence of rheumatoid arthritis among patients with recent-onset arthritis: data from the ESPOIR cohort

D. Guellec, G. Carvajal-Alegria, C. Daien, L. Gossec, F. Guillemin, F. Berenbaum, A. Constantin, P. Dieude, M. Dougados, R. M. Flipo, P. Goupille, X. Mariette, C. Richez, O. Vittecoq, B. Combe, A. Saraux

Summary: In patients with recent-onset arthritis, a self-reported familial occurrence of rheumatoid arthritis (RA) is associated with a higher prevalence of extra articular manifestations (EAMs), a higher likelihood of severe EAMs, and a higher probability of initiating targeted DMARD treatment over time.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (2023)

No Data Available